Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Amneal Pharmaceuticals, Inc. (AMRX)
A forensic read on Amneal Pharmaceuticals, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
3.7
Distress distance
Clean
Earnings quality
5
Forensic signals
47.3
P / E (ttm)
$5.8B
Market cap
8.0%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Amneal Pharmaceuticals, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 3.7, placing it in the Safe zone. 5 forensic signals were flagged in its latest SEC filings, led by shareholder returns — halted.
What the filings flag
stopped
FY2018→FY2020
Shareholder returns — halted.Capital returns have STOPPED — $183M of buybacks + dividends in FY2018, but ~$0 in FY2020. A halt usually means the company is conserving cash.
14.1%
FY2025
Return on invested capital.Return on invested capital is 14.1% in the latest fiscal year and rising from -2% — a modest positive spread over its ~10% cost of capital — growth adds value, though not dramatically.
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed +115% over the last 3 years to FY2025, but that includes a large one-time change around FY2024 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +29.1%/yr figure isn't a real buyback/dilution read here.
1.1% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 1.1% of revenue and 12% of free cash flow in FY2025 — about $0.10 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 7.1% a year and is falling.
$5M
FY2019–FY2019
Goodwill impairments.Took $5M of goodwill writedowns across 1 year (FY2019 ($5M)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$3.02B
Revenue Growth YoY+8.0%
Revenue CAGR (3yr)+10.9%
Net Margin2.4%
Free Cash Flow$269.9M
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Amneal Pharmaceuticals, Inc.'s actual 10-K/10-Q/8-K filings?